Invention Grant
US09573970B2 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate
有权
4- {4 - [（1E）-4-（2,9-二氮杂螺[5.5]十一烷-2-基）丁-1-烯-1-基] -2-甲基苄基} -5-（丙-2-基） 吡啶-3-基）-1H-吡唑-3-基β-D吡喃葡萄糖苷
![4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate](/docs/US/2017-02-21/US09573970B2/abs.jpg.600x600.jpg)
- Patent Title: 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate
- Patent Title (中): 4- {4 - [（1E）-4-（2,9-二氮杂螺[5.5]十一烷-2-基）丁-1-烯-1-基] -2-甲基苄基} -5-（丙-2-基） 吡啶-3-基）-1H-吡唑-3-基β-D吡喃葡萄糖苷
-
Application No.: US15026427Application Date: 2014-10-30
-
Publication No.: US09573970B2Publication Date: 2017-02-21
- Inventor: Susan Marie Reutzel-Edens
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Nelsen L Lentz
- International Application: PCT/US2014/063161 WO 20141030
- International Announcement: WO2015/069541 WO 20150514
- Main IPC: C07H17/02
- IPC: C07H17/02
![4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate](/abs-image/US/2017/02/21/US09573970B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides a compound of Formula I or hydrate thereof, useful for the treatment of diabetes.
Public/Granted literature
- US20160215011A1 4--5-(PROPAN-2-YL)-1H-PYRAZOL-3-YL BETA-D GLUCOPYRANOSIDE ACETATE Public/Granted day:2016-07-28
Information query
